Axsome Therapeutics, Inc.
AXSMNasdaq
$230.00
↓ -3.0%Jul 17 close · end-of-day
Price
1Y↑ +106.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.8B
Enterprise Value
$11.7B
P/E
—
P/S
16.6
P/B
215.7
EV/EBITDA
—
PEG
—
FCF Yield
-0.6%
Dividend Yield
—
Revenue (TTM)
$708.2M
Net Income (TTM)
-$188.3M
Free Cash Flow (TTM)
-$71.0M
Gross Margin
—
Operating Margin
-24.4%
Net Margin
-26.6%
ROE
-345.0%
ROIC
—
Debt / Equity
3.4
Net Cash
$117.3M
Return 1Y
+104.9%
Company profile
Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.
- CEO
- Herriott Tabuteau
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 380
- Headquarters
- New York
- Website
- axsome.com
Management & directors
- Tabuteau HerriotChief Executive Officer
- Pizzie NickChief Financial Officer
- Jacobson Mark L.Chief Operating Officer
- Maizel AriChief Commercial Officer
- Murdock Hunter R.General Counsel
Roles derived from SEC Form 4 filings.
Earnings
AXSM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$191.2M↑ +57.4%
Diluted EPS-$1.26↑ +3.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $270.6M | $385.7M | $638.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$99.1M | -$124.7M | -$179.8M | -$231.8M | -$280.6M | -$166.8M |
| Net income | -$102.9M | -$130.4M | -$187.1M | -$239.2M | -$287.2M | -$183.2M |
| Diluted EPS | -$2.77 | -$3.47 | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
| Operating cash flow | -$78.5M | -$108.2M | -$116.5M | -$145.1M | -$128.4M | -$93.4M |
| Free cash flow | -$78.5M | -$108.5M | -$117.2M | -$145.7M | -$128.7M | -$93.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -85.7% | -72.7% | -26.1% |
| Net margin | — | — | — | -88.4% | -74.5% | -28.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.2M | $104.8M | $118.8M | $121.5M | $150.0M | $171.0M | $196.0M | $191.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$78.0M | -$62.6M | -$72.6M | -$57.0M | -$36.7M | -$46.1M | -$27.0M | -$63.4M |
| Net income | -$79.3M | -$64.6M | -$74.9M | -$59.4M | -$48.0M | -$47.2M | -$28.6M | -$64.5M |
| Diluted EPS | -$1.67 | -$1.34 | -$1.54 | -$1.22 | -$0.97 | -$0.94 | -$0.55 | -$1.26 |
| Operating cash flow | -$30.1M | -$18.6M | -$26.2M | -$43.4M | -$32.4M | $1.0M | -$18.7M | -$20.7M |
| Free cash flow | -$30.2M | -$18.7M | -$26.2M | -$43.7M | -$32.4M | $988,000.00 | -$18.7M | -$20.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -89.5% | -59.8% | -61.1% | -46.9% | -24.5% | -27.0% | -13.8% | -33.1% |
| Net margin | -91.0% | -61.7% | -63.1% | -48.9% | -32.0% | -27.6% | -14.6% | -33.8% |
Company news
Jul 18, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | TABUTEAU HERRIOT· Chief Executive Officer | Sale | 49,666 | $240.25 | $11.9M | filing |
| 2026-07-01 | TABUTEAU HERRIOT· Chief Executive Officer | Option exercise | 49,666 | $4.95 | $245,846.70 | filing |
| 2026-06-11 | JEFFS ROGER | Sale | 286 | $249.12 | $71,248.32 | filing |
| 2026-06-10 | Coleman Mark | Sale | 643 | $249.00 | $160,107.00 | filing |
| 2026-06-10 | Mahony Susan | Sale | 300 | $246.18 | $73,854.00 | filing |
| 2026-06-10 | JEFFS ROGER | Sale | 286 | $246.18 | $70,407.48 | filing |
| 2026-06-09 | TABUTEAU HERRIOT· Chief Executive Officer | Sale | 49,670 | $241.01 | $12.0M | filing |
| 2026-06-09 | Pizzie Nick· Chief Financial Officer | Sale | 33,000 | $240.09 | $7.9M | filing |
| 2026-06-09 | TABUTEAU HERRIOT· Chief Executive Officer | Option exercise | 49,670 | $4.95 | $245,866.50 | filing |
| 2026-06-09 | Pizzie Nick· Chief Financial Officer | Option exercise | 33,000 | $3.50 | $115,500.00 | filing |
| 2026-06-09 | Mahony Susan | Sale | 300 | $237.21 | $71,163.00 | filing |
| 2026-06-08 | Mahony Susan | Option exercise | 1,429 | — | — | filing |
| 2026-06-08 | JEFFS ROGER | Option exercise | 1,429 | — | — | filing |
| 2026-06-08 | Saad Mark E | Option exercise | 1,429 | — | — | filing |
| 2026-06-08 | Coleman Mark | Option exercise | 1,429 | — | — | filing |
| 2026-06-02 | Coleman Mark | Sale | 5,537 | $223.39 | $1.2M | filing |
| 2026-06-01 | Coleman Mark | Sale | 6,000 | $230.30 | $1.4M | filing |
| 2026-05-29 | Coleman Mark | Sale | 6,000 | $233.46 | $1.4M | filing |
| 2026-05-05 | Jacobson Mark L.· Chief Operating Officer | Sale | 233 | $228.18 | $53,165.94 | filing |
| 2026-05-05 | Jacobson Mark L.· Chief Operating Officer | Option exercise | 233 | $12.95 | $3,017.35 | filing |
| 2026-05-04 | Jacobson Mark L.· Chief Operating Officer | Sale | 4,517 | $227.94 | $1.0M | filing |
| 2026-05-04 | Jacobson Mark L.· Chief Operating Officer | Option exercise | 4,517 | $12.95 | $58,495.15 | filing |
| 2026-04-22 | Maizel Ari· Chief Commercial Officer | Sale | 7,500 | $182.42 | $1.4M | filing |
| 2026-04-22 | Maizel Ari· Chief Commercial Officer | Option exercise | 7,500 | $70.73 | $530,475.00 | filing |
| 2026-02-26 | Jacobson Mark L.· Chief Operating Officer | Sale | 35,378 | $161.88 | $5.7M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.